Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gyula Ostoros

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)|August 18, 2014
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE)Veronika Sarosi, Gyorgy Losonczy, Eva Francovszky, et al.
Magyar Onkologia|March 12, 2026
[Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for the development of a national guideline.]László Mangel, Tímea Balatoni, Krisztina Bogos, et al.
Future Oncology (London, England)|October 14, 2011
Lung cancer in never smokersSzilvia Torok, Balazs Hegedus, Viktoria Laszlo, et al.
Anticancer Research|December 13, 2005
Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programmeGyula Ostoros, Revekka Harisi, Gabor Kovacs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III StudyNicholas Thatcher, Jerome H Goldschmidt, Michael Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancerFerenc Renyi-Vamos, Jozsef Tovari, Janos Fillinger, et al.
Expert Review of Anticancer Therapy|October 18, 2023
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysisGyula Ostoros, Robert Hettle, Nefeli Georgoulia, et al.
Expert Opinion on Investigational Drugs|November 3, 2009
Antivascular agents for non-small-cell lung cancer: current status and future directionsEitan Amir, Laszlo Mandoky, Fiona Blackhall, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR statusJean-Yves Douillard, Gyula Ostoros, Manuel Cobo, et al.
BMC Cancer|May 27, 2018
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trialZsolt Markóczy, Veronika Sárosi, Iveta Kudaba, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|August 18, 2014
Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE)Veronika Sarosi, Gyorgy Losonczy, Eva Francovszky, et al.
Magyar Onkologia|March 12, 2026
[Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for the development of a national guideline.]László Mangel, Tímea Balatoni, Krisztina Bogos, et al.
Future Oncology (London, England)|October 14, 2011
Lung cancer in never smokersSzilvia Torok, Balazs Hegedus, Viktoria Laszlo, et al.
Anticancer Research|December 13, 2005
Inhibition of EGFR tyrosine-kinase in NSCLC treatment: the Hungarian experience with gefitinib in the context of an expanded access programmeGyula Ostoros, Revekka Harisi, Gabor Kovacs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III StudyNicholas Thatcher, Jerome H Goldschmidt, Michael Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancerFerenc Renyi-Vamos, Jozsef Tovari, Janos Fillinger, et al.
Expert Review of Anticancer Therapy|October 18, 2023
Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysisGyula Ostoros, Robert Hettle, Nefeli Georgoulia, et al.
Expert Opinion on Investigational Drugs|November 3, 2009
Antivascular agents for non-small-cell lung cancer: current status and future directionsEitan Amir, Laszlo Mandoky, Fiona Blackhall, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 15, 2014
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR statusJean-Yves Douillard, Gyula Ostoros, Manuel Cobo, et al.
BMC Cancer|May 27, 2018
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trialZsolt Markóczy, Veronika Sárosi, Iveta Kudaba, et al.
Pageof 6